<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947124</url>
  </required_header>
  <id_info>
    <org_study_id>QC-203</org_study_id>
    <nct_id>NCT04947124</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101</brief_title>
  <official_title>Masked, Randomized, Single-site, Crossover Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 Dosed for 14 Days in Adult Subjects With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qlaris Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qlaris Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge&#xD;
      Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masked, randomized, single site, crossover study to compare 2 concentrations of QLS-101.&#xD;
      Subjects will be randomized to one of 2 concentrations of QLS-101 for the first 14 days of&#xD;
      daily dosing, and after a 14-day washout period they will be crossed over to the other&#xD;
      concentration for another 14 days of daily dosing. Dose assignment is masked to patient and&#xD;
      investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients take 2 different doses of investigational product at distinct treatment periods. Dose is masked.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Masked investigational product labeling.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular AEs</measure>
    <time_frame>56 days, including a 14-day washout</time_frame>
    <description>Standard safety endpoint, ocular AEs, (including elevated IOP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>56 days, including a 14-day washout</time_frame>
    <description>Standard safety endpoint, best corrected visual acuity, Snellen score, change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enhance depth imaging optical coherence tomography (EDI-OCT)</measure>
    <time_frame>56 days, including a 14-day washout</time_frame>
    <description>Standard safety endpoint, EDI-OCT, corneal thickness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit lamp exam</measure>
    <time_frame>56 days, including a 14-day washout</time_frame>
    <description>Standard safety endpoint, slit lamp exam, abnormalities, changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dilated fundus exam</measure>
    <time_frame>56 days, including a 14-day washout</time_frame>
    <description>Fundus exam, abnormalities, changes from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular hypotensive efficacy</measure>
    <time_frame>14 days after each dosing timepoint is completed</time_frame>
    <description>Mean change in IOP from baseline following 14 days dosing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Sturge-Weber Syndrome (SWS)</condition>
  <condition>Glaucoma</condition>
  <condition>Glaucoma Congenital</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>1% QLS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosed once a day for 14 days as either first or second dosing period per randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% QLS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosed once a day for 14 as either first or second dosing period per randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLS-101ophthalmic solution 1%</intervention_name>
    <description>QLS-101ophthalmic solution 1.0%</description>
    <arm_group_label>1% QLS-101</arm_group_label>
    <other_name>QLS-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLS-101ophthalmic solution 2%</intervention_name>
    <description>QLS-101ophthalmic solution 2.0%</description>
    <arm_group_label>2% QLS-101</arm_group_label>
    <other_name>QLS-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with SWS.&#xD;
&#xD;
          -  Elevated intraocular pressure (IOP)&#xD;
&#xD;
          -  Willing to continue current dosing regimen of IOP-lowering medications&#xD;
&#xD;
          -  Willing to refrain from contact lens use in the study eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IOP with variability of &gt; 4 mm Hg&#xD;
&#xD;
          -  Expected to undergo IOP-lowering surgery&#xD;
&#xD;
          -  Incisional or laser surgery of any type&#xD;
&#xD;
          -  Ocular infection, inflammation, clinically significant blepharitis or conjunctivitis&#xD;
&#xD;
          -  A history of herpes simplex keratitis in either eye.&#xD;
&#xD;
          -  History of or active clinically significant ocular disease&#xD;
&#xD;
          -  Use of topical ocular corticosteroids in the 6 weeks prior to Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheryl St John</last_name>
    <phone>9789302103</phone>
    <email>cstjohn@qlaris.bio</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Brandano</last_name>
    <phone>978-930-2103</phone>
    <email>lbrandano@qlaris.bio</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://qlaris.bio/pipeline</url>
    <description>Qlaris Bio</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sturge-Weber Syndrome</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Elevated IOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sturge-Weber Syndrome</mesh_term>
    <mesh_term>Brain Stem Infarctions</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hydrophthalmos</mesh_term>
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

